Venrock Adviser, LLC
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), Venrock Adviser, LLC reported 33 stock positions worth $2.7 billion. Its top holding was Apogee Therapeutics (APGE) at 26.7% of the portfolio, followed by Erasca (ERAS, 9.9%) and Oruka Therapeutics (ORKA, 7.6%). Compared with Q4 2025, it opened 8 new positions, sold out of 2, added to 6 and reduced 6. The biggest buy was a new position in Damora Therapeutics (DMRA) and the biggest sale an exit from Upstream Bio (UPB).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001615982
- Portfolio Value
- $2.7B (Q1 2026)
- SEC Filing
- 0001615982-26-000011 ↗ filed May 15, 2026
Holdings Value
Holdings 33 stocks · $2.7B
| APGE Apogee Therapeutics Inc. | 26.68% | 8,493,321 | $714.9M | No change |
| ERAS Erasca Inc. | 9.89% | 16,382,812 | $265.1M | Reduce -8.3% |
| ORKA Oruka Therapeutics Inc. | 7.59% | 4,148,428 | $203.5M | No change |
| SYRE Spyre Therapeutics Inc. | 6.94% | 3,685,448 | $185.9M | No change |
| KALV Kalvista Pharmaceuticals Inc. | 4.86% | 6,474,485 | $130.3M | Reduce -3.8% |
| DNTH Dianthus Therapeutics Inc. | 3.70% | 1,180,000 | $99.0M | Add +18.0% |
| DMRA Damora Therapeutics Inc. | 3.48% | 3,603,595 | $93.3M | New |
| OCUL Ocular Therapeutix Inc. | 3.27% | 10,346,926 | $87.6M | Add +41.4% |
| COGT Cogent Biosciences Inc. | 2.87% | 2,000,000 | $77.0M | No change |
| VRDN Viridian Therapeutics Inc. | 2.83% | 3,882,709 | $75.9M | No change |
| SVRA Savara Inc. | 2.80% | 13,740,375 | $75.0M | No change |
| ELVN Enliven Therapeutics Inc. | 2.53% | 1,726,331 | $67.7M | Reduce -46.5% |
| ORIC Oric Pharmaceuticals Inc. | 2.04% | 4,319,765 | $54.7M | Reduce -23.9% |
| VOR Vor Biopharma Inc. | 2.03% | 3,041,719 | $54.3M | Add +56.5% |
| MAZE Maze Therapeutics Inc. | 1.78% | 1,602,034 | $47.8M | Add +3.5% |
| CTMX Cytomx Therapeutics Inc. | 1.75% | 9,982,124 | $46.9M | Reduce -35.9% |
| JBIO Jade Biosciences Inc. | 1.69% | 3,220,364 | $45.2M | No change |
| DYN Dyne Therapeutics Inc. | 1.47% | 2,173,913 | $39.4M | No change |
| CBIO Crescent Biopharma Inc. | 1.46% | 2,133,576 | $39.2M | No change |
| ZURA Zura Bio Ltd. | 1.43% | 6,434,990 | $38.3M | Add +20.4% |
| RLMD Relmada Therapeutics Inc. | 1.26% | 4,843,380 | $33.7M | New |
| ENGN Engene Holdings Inc. | 1.21% | 4,771,414 | $32.5M | No change |
| TENX Tenax Therapeutics Inc. | 1.00% | 1,675,262 | $26.8M | New |
| ANL Adlai Nortye Group Ltd. | 0.83% | 3,212,731 | $22.2M | New |
| IPSC Century Therapeutics Inc. | 0.73% | 8,695,652 | $19.7M | New |
| CGEM Cullinan Therapeutics Inc. | 0.73% | 1,379,965 | $19.6M | No change |
| HELP Cybin Inc. | 0.69% | 3,851,654 | $18.5M | Add +0.3% |
| SRZN Surrozen Inc. | 0.69% | 632,931 | $18.4M | No change |
| SEPN Septerna Inc. | 0.45% | 506,056 | $12.2M | Reduce -17.1% |
| KRRO Korro Bio Inc. | 0.43% | 1,009,500 | $11.4M | New |
| ANRO Alto Neuroscience Inc. | 0.42% | 500,000 | $11.2M | New |
| ARTV Artiva Biotherapeutics Inc. | 0.39% | 1,609,569 | $10.4M | No change |
| XFOR X4 Pharmaceuticals Inc. | 0.05% | 330,525 | $1.4M | New |
Portfolio Sells Q4 2025 → Q1 2026
| UPB Upstream Bio Inc. | Sold out | 0.00% | −1.57 |
| CTMX Cytomx Therapeutics Inc. | Reduce -35.9% | 1.75% | −1.52 |
| KALV Kalvista Pharmaceuticals Inc. | Reduce -3.8% | 4.86% | −0.50 |
| SEPN Septerna Inc. | Reduce -17.1% | 0.45% | −0.39 |
| ORIC Oric Pharmaceuticals Inc. | Reduce -23.9% | 2.04% | −0.25 |
| CASIF Casi Pharmaceuticals Inc. | Sold out | 0.00% | −0.04 |
| ELVN Enliven Therapeutics Inc. | Reduce -46.5% | 2.53% | +0.07 |
| ERAS Erasca Inc. | Reduce -8.3% | 9.89% | +6.61 |
Portfolio Buys Q4 2025 → Q1 2026
| DMRA Damora Therapeutics Inc. | New | 3.48% | +3.48 |
| DNTH Dianthus Therapeutics Inc. | Add +18.0% | 3.70% | +1.66 |
| RLMD Relmada Therapeutics Inc. | New | 1.26% | +1.26 |
| TENX Tenax Therapeutics Inc. | New | 1.00% | +1.00 |
| ANL Adlai Nortye Group Ltd. | New | 0.83% | +0.83 |
| VOR Vor Biopharma Inc. | Add +56.5% | 2.03% | +0.77 |
| IPSC Century Therapeutics Inc. | New | 0.73% | +0.73 |
| KRRO Korro Bio Inc. | New | 0.43% | +0.43 |
| ANRO Alto Neuroscience Inc. | New | 0.42% | +0.42 |
| XFOR X4 Pharmaceuticals Inc. | New | 0.05% | +0.05 |
| ZURA Zura Bio Ltd. | Add +20.4% | 1.43% | +0.05 |
| HELP Cybin Inc. | Add +0.3% | 0.69% | −0.86 |
| OCUL Ocular Therapeutix Inc. | Add +41.4% | 3.27% | −1.12 |
| MAZE Maze Therapeutics Inc. | Add +3.5% | 1.78% | −1.38 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 33 | $3.3B | APGE, ORKA, ERAS, SYRE, DNTH |
| Q1 2026 | 33 | $2.7B | APGE, ERAS, ORKA, SYRE, KALV |
| Q4 2025 | 27 | $2.0B | APGE, ORKA, VRDN, SYRE, KALV |
| Q3 2025 | 33 | $1.8B | APGE, MTSR, OCUL, CDTX, VRDN |
| Q2 2025 | 31 | $1.3B | APGE, OCUL, MTSR, ELVN, KALV |
| Q1 2025 | 37 | $1.2B | APGE, MTSR, OCUL, ELVN, KALV |
| Q4 2024 | 37 | $1.5B | APGE, OCUL, ELVN, PRAX, VRDN |
| Q3 2024 | 38 | $1.9B | APGE, OCUL, ELVN, VRDN, APLT |
| Q2 2024 | 35 | $1.6B | APGE, ELVN, FDMT, OCUL, DYN |
| Q1 2024 | 38 | $2.1B | APGE, FDMT, OCUL, SYRE, MRUS |